In life science industries, many believe that regulatory inspections are focused more on postmarket activities. This attitude isn’t surprising; however, its results can be detrimental. Many companies elect to focus on bolstering their postmarket compliance, allowing other regulatory activities such as design controls to lapse or deteriorate over time. Unfortunately for these companies, the truth about regulatory inspections is starkly different than their beliefs, and that can come back to haunt them.
In FY2017, inspectional observations for medical devices saw citations for nearly every part of FDA’s Design Controls Regulation. Of the 1,030 device observations from FY2017, 438 were Design Controls citations. This data tells us one important thing: FDA is keeping an eye on more than just postmarket compliance, and companies need to be closely surveying their design control activities. Otherwise, there are three pain points that affect your life science organization.
A 483 can be depleting to your organization’s resources as well as time—both in the response and other adverse results. The diversion of personnel, tools, and equipment to successfully enact the corrective action committed to in the response can put a strain on already thin budgets, especially for smaller organizations. Likewise, the publication of your warning letter can negatively alter your brand status and value, dissuading consumers from your products and services.
In a best-case scenario, product design issues could be resolved through such avenues as:
While it’s tempting to hope for a simple resolution to issues in your product’s design, chances are good that your remediation activities might be more involved. Product recalls, for example, cost significant time and resources to resolve. And, in extreme cases, remediation that reveals fundamental design flaws can result in both marketed and in-development products having to go back to the drawing board.
If your organization receives a related citation, there’s a good chance you’ll have to start assessing the impact of that breakdown throughout your quality system. Ineffective, incomplete, or absent design controls activities could affect everything from risk management and manufacturing to postmarket surveillance. These issues might not even be apparent until a 483 is handed down, so whatever remediation it takes to correct them first needs to identify any influence they’ve had on the quality system.